

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 235/14, 401/06, 409/14, 405/14, A61K 31/415, 31/47	A1	(11) International Publication Number: WO 94/21615 (43) International Publication Date: 29 September 1994 (29.09.94)
(21) International Application Number: PCT/GB94/00528 (22) International Filing Date: 16 March 1994 (16.03.94) (30) Priority Data: 9305628.1 18 March 1993 (18.03.93) GB 9316258.4 5 August 1993 (05.08.93) GB (71) Applicant (for all designated States except US): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): KULAGOWSKI, Janusz, Jozef [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). LEESON, Paul, David [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). (74) Agent: THOMPSON, John; Merck & Co., Inc., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: BENZIMIDAZOLE DERIVATIVES (57) Abstract A class of chemical compounds comprising a benzimidazole moiety and a substituted heterocyclic moiety, linked via the 3-position of the benzimidazole moiety by a methylene group, are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

BENZIMIDAZOLE DERIVATIVES

5 This invention relates to a particular class of
heteroaromatic compounds. More particularly, the
invention is concerned with substituted benzimidazole
derivatives which are ligands for dopamine receptor
subtypes within the body and are therefore of use in the
treatment and/or prevention of disorders of the dopamine
10 system, including schizophrenia, depression, nausea,
Parkinson's disease, tardive dyskinesias and
extrapyramidal side-effects associated with treatment by
conventional neuroleptic agents, neuroleptic malignant
syndrome, and disorders of hypothalamic-pituitary
15 function such as hyperprolactinaemia and amenorrhoea.

Upper gastrointestinal tract motility is
believed to be under the control of the dopamine system.
The compounds according to the present invention may thus
be of use in the prevention and/or treatment of
20 gastrointestinal disorders, and the facilitation of
gastric emptying.

Dependence-inducing agents such as cocaine and
amphetamine have been shown to interact with the dopamine
system. Compounds capable of counteracting this effect,
25 including the compounds in accordance with the present
invention, may accordingly be of value in the prevention
or reduction of dependence on a dependence-inducing
agent.

Dopamine is known to be a peripheral
30 vasodilator; for example, it has been shown to exert a
dilatory effect on the renal vascular bed. This implies
that the compounds of the present invention may be
beneficial in controlling vascular blood flow.

The localisation of dopamine receptor mRNA in
35 rat heart and large vessels has been noted. This
suggests a role for dopamine receptor ligands in

- 2 -

controlling cardiovascular function, either by affecting cardiac and smooth muscle contractility or by modulating the secretion of vasoactive substances. The compounds according to the present invention may therefore be of assistance in the prevention and/or treatment of such conditions as hypertension and congestive heart failure.

Molecular biological techniques have revealed the existence of several subtypes of the dopamine receptor. The dopamine D₁ receptor subtype has been shown to occur in at least two discrete forms. Two forms of the D₂ receptor subtype, and at least one form of the D₃ receptor subtype, have also been discovered. More recently, the D₄ (Van Tol *et al.*, *Nature* (London), 1991, 350, 610) and D₅ (Sunahara *et al.*, *Nature* (London), 1991, 350, 614) receptor subtypes have been described.


JP-A-61-227565 and JP-A-64-52718 describe in generic terms various [4-substituted-piperidin-1-yl-alkyl]-benzimidazole derivatives, which are stated to be effective against certain cardiovascular complaints.

There is, however, no suggestion in either of these publications that the compounds described therein might be of any assistance in solving the problem of providing compounds which are ligands for dopamine receptor subtypes within the body and thus effective in the treatment and/or prevention of disorders of the dopamine system.

The compounds in accordance with the present invention, being ligands for dopamine receptor subtypes within the body, are accordingly of use in the treatment and/or prevention of disorders of the dopamine system.

The present invention accordingly provides a compound of formula I, or a salt or prodrug thereof:

- 3 -




(1)

wherein


E represents $-\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2-$;R represents hydrogen or C_{1-6} alkyl;

Q represents a moiety of formula Qa, Qb or Qc:


15



(Qa)



(Qb)



(Qc)

in which the broken line represents an optional chemical bond;

25

R^1 represents hydrogen, or an optionally substituted C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl, aryl, aryl(C_{1-6})alkyl, aryl(C_{1-6})alkoxy, aryl(C_{2-6})alkenyl, aryl(C_{2-6})alkynyl, C_{3-7} heterocycloalkyl(C_{1-6})alkyl, heteroaryl, heteroaryl(C_{1-6})alkyl, heteroaryl(C_{2-6})alkenyl or heteroaryl(C_{2-6})alkynyl group;

30

R^2 represents an optionally substituted C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{3-7} heterocycloalkyl(C_{1-6})alkyl group; or aryl, aryl(C_{1-6})alkyl, aryloxy(C_{1-6})alkyl, aryl(C_{1-6})alkoxy, aryl(C_{2-6})alkenyl, aryl(C_{2-6})alkynyl, heteroaryl,

35

- 4 -

heteroaryl(C₁₋₆)alkyl, heteroaryl(C₂₋₆)alkenyl or heteroaryl(C₂₋₆)alkynyl, any of which groups may be optionally substituted on the aromatic moiety;

5 R³, R⁴ and R⁵ independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR^a, -SR^a, -SOR^a, -SO₂R^a, -SO₂NR^aR^b, -NR^aR^b, -NR^aCOR^b, -NR^aCO₂R^b, -COR^a, -CO₂R^a or -CONR^aR^b;

10 Z represents -CH₂- or -CH₂CH₂-;
R⁶ represents hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl, aryl(C₁₋₆)alkyl or halogen; and

R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group.

15 The present invention also provides compounds of formula I as defined above, and salts and prodrugs thereof, wherein R² is other than an aryloxy(C₁₋₆)alkyl group, optionally substituted on the aromatic moiety.

For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts.
20 Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for
25 example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric
30 acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g.
35 calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

- 5 -

The term "hydrocarbon" as used herein includes straight-chained, branched and cyclic groups containing up to 18 carbon atoms, suitably up to 15 carbon atoms, and conveniently up to 12 carbon atoms. Suitable hydrocarbon groups include C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkyl(C₁₋₆)alkyl, aryl, aryl(C₁₋₆)alkyl, aryl(C₂₋₆)alkenyl and aryl(C₂₋₆)alkynyl.

The expression "a heterocyclic group" as used herein includes cyclic groups containing up to 18 carbon atoms and at least one heteroatom preferably selected from oxygen, nitrogen and sulphur. The heterocyclic group suitably contains up to 15 carbon atoms and conveniently up to 12 carbon atoms, and is preferably linked through carbon. Examples of suitable heterocyclic groups include C₃₋₇ heterocycloalkyl, C₃₋₇ heterocycloalkyl(C₁₋₆)alkyl, heteroaryl, heteroaryl(C₁₋₆)alkyl, heteroaryl(C₂₋₆)alkenyl and heteroaryl(C₂₋₆)alkynyl groups.

Suitable alkyl groups within the scope of the term "hydrocarbon" and within the definition of the substituents R, R¹, R² and R⁶ include straight-chained and branched alkyl groups containing from 1 to 6 carbon atoms. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl and butyl groups. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl.

Suitable alkenyl groups within the scope of the term "hydrocarbon" and within the definition of the substituents R¹ and R² include straight-chained and branched alkenyl groups containing from 2 to 6 carbon atoms. Typical examples include vinyl and allyl groups.

Suitable alkynyl groups within the scope of the term "hydrocarbon" and within the definition of the substituents R¹ and R² include straight-chained and branched alkynyl groups containing from 2 to 6 carbon

- 6 -

atoms. Typical examples include ethynyl and propargyl groups.

Suitable cycloalkyl groups include groups containing from 3 to 7 carbon atoms. Particular
5 cycloalkyl groups are cyclopropyl and cyclohexyl.

Particular aryl groups within the scope of the term "hydrocarbon" and within the definition of the substituents R^1 , R^2 and R^6 include phenyl and naphthyl.

Particular aryl(C_{1-6})alkyl groups within the
10 scope of the term "hydrocarbon" and within the definition of the substituents R^1 , R^2 and R^6 include benzyl, naphthylmethyl, phenethyl and phenylpropyl.

A particular aryl(C_{2-6})alkenyl group within the scope of the term "hydrocarbon" and within the definition
15 of the substituents R^1 and R^2 is phenylethenyl.

A particular aryl(C_{2-6})alkynyl group within the scope of the term "hydrocarbon" and within the definition of the substituents R^1 and R^2 is phenylethynyl.

Suitable heterocycloalkyl groups include
20 azetidiny, pyrrolidyl, piperidyl, piperaziny, morpholinyl and tetrahydrofuryl groups.

A particular C_{3-7} heterocycloalkyl(C_{1-6})alkyl group within the scope of the expression "a heterocyclic group" and within the definition of the substituents R^1
25 and R^2 is tetrahydrofurylethyl.

Suitable heteroaryl groups within the scope of the expression "a heterocyclic group" and within the definition of the substituents R^1 and R^2 include pyridyl, quinolyl, isoquinolyl, pyridaziny, pyrimidinyl,
30 pyraziny, pyranyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, indolyl, indazolyl, imidazolyl, benzimidazolyl, oxadiazolyl and thiadiazolyl groups.

Particular heteroaryl(C_{1-6})alkyl groups within the scope of the expression "a heterocyclic group" and
35 within the definition of the substituents R^1 and R^2

- 7 -

include thienylmethyl, pyridylmethyl, pyrimidinylmethyl and pyrazinylmethyl.

Particular heteroaryl(C₂₋₆)alkenyl groups within the scope of the expression "a heterocyclic group" and within the definition of the substituents R¹ and R² include furylethenyl and thienylethenyl.

The hydrocarbon and heterocyclic groups, as well as the substituents R¹ and R², may in turn be optionally substituted by one or more groups selected from C₁₋₆ alkyl, adamantyl, phenyl, aryl(C₁₋₆)alkyl, halogen, C₁₋₆ haloalkyl, C₁₋₆ aminoalkyl, trifluoromethyl, hydroxy, C₁₋₆ alkoxy, aryloxy, keto, C₁₋₃ alkylenedioxy, nitro, cyano, carboxy, C₂₋₆ alkoxycarbonyl, C₂₋₆ alkoxycarbonyl(C₁₋₆)alkyl, C₂₋₆ alkylcarbonyloxy, arylcarbonyloxy, C₂₋₆ alkylcarbonyl, arylcarbonyl, C₁₋₆ alkylthio, C₁₋₆ alkylsulphiny, C₁₋₆ alkylsulphonyl, arylsulphonyl, trifluoromethane-sulphonyloxy, -NR^VR^W, -NR^VCOR^W, -NR^VCO₂R^W, -NR^VSO₂R^W, -CH₂NR^VSO₂R^W, -NHCONR^VR^W, -PO(OR^V)(OR^W), -CONR^VR^W, -SO₂NR^VR^W and -CH₂SO₂NR^VR^W, in which R^V and R^W independently represent hydrogen, C₁₋₆ alkyl, aryl or aryl(C₁₋₆)alkyl.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially chlorine.

The present invention includes within its scope prodrugs of the compounds of formula I above. In general, such prodrugs will be functional derivatives of the compounds of formula I which are readily convertible in vivo into the required compound of formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

Where the compounds according to the invention have at least one asymmetric centre, they may accordingly

- 8 -

exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

Suitably, the substituent R represents hydrogen or methyl, especially hydrogen.

Suitably, the substituent R¹ represents hydrogen.

Suitably, the substituent R² represents an optionally substituted C₁₋₆ alkyl group; or aryl, aryl(C₁₋₆)alkyl, aryloxy(C₁₋₆)alkyl, aryl(C₁₋₆)alkoxy, aryl(C₂₋₆)alkenyl, aryl(C₂₋₆)alkynyl, heteroaryl or heteroaryl(C₂₋₆)alkenyl, any of which groups may be optionally substituted on the aromatic moiety. Examples of optional substituents on the group R² include C₁₋₆ alkyl, halogen, trifluoromethyl, C₁₋₆ alkoxy, nitro, C₁₋₆ alkylamino and di(C₁₋₆)alkylamino.


Particular values of R² include methyl, ethyl, n-propyl, isopropyl, phenyl, chlorophenyl, ethylphenyl, methoxyphenyl, nitrophenyl, benzyl, chlorobenzyl, phenethyl, phenylpropyl, phenoxyethyl, benzyloxy, phenylethenyl, methoxy-phenylethenyl, phenylethynyl, benzofuryl, benzthienyl, furylethenyl, methyl-furylethenyl and thienylethenyl.

Suitable values for the substituents R³, R⁴ and R⁵ include hydrogen, halogen, cyano, nitro, trifluoromethyl, amino, C₁₋₆ alkylamino, di(C₁₋₆)alkylamino, C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl(C₁₋₆)alkoxy and C₂₋₆ alkylcarbonyl. Particular values include hydrogen, fluoro, chloro, methyl, ethyl, methoxy and benzyloxy.

Particular values of R⁶ include hydrogen, phenyl, chloro and bromo.

- 9 -

One sub-class of compounds according to the invention is represented by the compounds of formula IIA, and salts and prodrugs thereof:



(IIA)


wherein

E and R are as defined with reference to formula I above;


15 U represents $-(CH_2)_n-$, $-CH=CH-$ or $-C\equiv C-$;
n is zero, 1, 2 or 3;

$-X-Y-$ represents $-CH_2-CH-$ or $-CH=C-$;

T represents a group of formula (i), (ii),
20 (iii), (iv), (v) or (vi):




(i)




(ii)




(iii)



(iv)



(v)



(vi)

- 10 -


in which V represents oxygen, sulphur or NH; and

R^{13} and R^{17} independently represent hydrogen, halogen, cyano, nitro, trifluoromethyl, amino, C_{1-6} alkylamino, di(C_{1-6})alkylamino, C_{1-6} alkyl, C_{1-6} alkoxy, aryl(C_{1-6})alkoxy or C_{2-6} alkylcarbonyl.

Particular values of R^{13} include hydrogen, fluoro, chloro, methyl, ethyl, methoxy and benzyloxy.

Particular values of R^{17} include hydrogen, chloro, methyl, methoxy and nitro.

Another sub-class of compounds according to the invention is represented by the compounds of formula IIB, and salts and prodrugs thereof:



(I I B)

wherein

E and R are as defined with reference to formula I above;

A represents a moiety of formula $-(CH_2)_n-$, $-CH=CH-$, $-C\equiv C-$, $-O-(CH_2)_m-$ or $-(CH_2)_m-O-$;


m is 1, 2 or 3; and

n, X, Y, R^{13} and R^{17} are as defined with reference to formula IIA above.

In a subset of the compounds of formula IIB above, R represents hydrogen and A represents $-C\equiv C-$, $-CH=CH-$ or $-O-(CH_2)_m-$.

A particular subset of the compounds of formula IIA and IIB as defined above is represented by the compounds of formula IIC, and salts and prodrugs thereof:

- 11 -



(IIC)


wherein

E is as defined with reference to formula I above; and

15 n, X, Y, R¹³ and R¹⁷ are as defined with reference to formula IIA above.

A further sub-class of compounds according to the invention is represented by the compounds of formula IID, and salts and prodrugs thereof:

20



(IID)

30 wherein

E and Z are as defined with reference to formula I above;


R¹³ is as defined with reference to formula IIA above; and

35 R¹⁶ represents hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl, aryl(C₁₋₆)alkyl or halogen.

- 12 -

Particular values of R^{16} include hydrogen, phenyl, chloro and bromo, especially hydrogen.

A still further sub-class of compounds according to the invention is represented by the
 5 compounds of formula IIE, and salts and prodrugs thereof:



(I I E)

wherein

E is as defined with reference to formula I

above;

R^{13} and R^{17} are as defined with reference to
 20 formula IIA above; and
 m is 1, 2 or 3.

Specific compounds within the scope of the present invention include:

2-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)-
 25 benzimidazole;
 2-[4-(2-phenylethyl)piperidin-1-ylmethyl]benzimidazole;
 2-(4-phenyl-1,2,3,6-tetrahydropyrid-1-ylmethyl)-
 benzimidazole;
 5-chloro-2-(1,2,3,4-tetrahydroisoquinolin-2-
 30 ylmethyl)benzimidazole;
 5-methoxy-2-(1,2,3,4-tetrahydroisoquinolin-2-
 ylmethyl)benzimidazole;
 2-(1,2-dihydroisoindol-2-ylmethyl)benzimidazole;
 2-(4-benzylpiperidin-1-ylmethyl)benzimidazole;
 35 2-(4-benzyl-1,2,3,6-tetrahydropyrid-1-
 ylmethyl)benzimidazole;

- 13 -

- 2-[4-(3-phenylpropyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
2-[4-(2-phenylethyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
5 2-[4-(2-phenylethynyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
2-(4-benzyloxy-1,2,3,6-tetrahydropyrid-1-ylmethyl)benzimidazole;
2-[4-(3-phenylpropyl)piperidin-1-ylmethyl]benzimidazole;
10 2-(4-benzyloxypiperidin-1-ylmethyl)benzimidazole;
2-[4-(3-phenylpropylidene)piperidin-1-ylmethyl]benzimidazole;
2-[4-(E)-(2-phenylethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
15 1-methyl-2-[4-(E)-(2-phenylethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
2-[4-(benzothiophen-2-yl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
2-[4-(benzofuran-2-yl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
20 2-[4-(E)-(2-(thien-2-yl)ethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
2-[4-(E)-(2-(thien-3-yl)ethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
25 2-[4-(E)-(2-(furan-2-yl)ethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
2-[4-(E)-(2-(5-methylfuran-2-yl)ethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
2-[4-(E)-(2-(3-methoxyphenyl)ethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
30 2-(4-phenoxyethyl-1,2,3,6-tetrahydropyrid-1-ylmethyl)benzimidazole;
and salts and prodrugs thereof.

The invention also provides pharmaceutical
35 compositions comprising one or more compounds of this invention in association with a pharmaceutically

- 14 -

acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the compositions may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope

- 15 -


over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.


In the treatment of schizophrenia, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.05 to 100 mg/kg per day, and especially about 0.05 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day.

The compounds in accordance with the present invention may be prepared by a process which comprises reacting a compound of formula III with a compound of formula IV:

- 16 -



(III)



(IV)


wherein E, R, R³, R⁴ and R⁵ are as defined above, Q¹ represents the residue of a moiety of formula Qa to Qc as defined above, and L represents a suitable leaving group.

15 The leaving group L is suitably a halogen atom, e.g. chlorine.

The reaction is conveniently carried out by stirring the reactants under basic conditions in a suitable solvent, for example potassium carbonate in N,N-dimethylformamide, or triethylamine in tetrahydrofuran or acetonitrile.

20 In an alternative procedure, the compounds in accordance with the present invention may be prepared by a process which comprises reducing a compound of formula

25 V:




(V)

35 wherein R, R³, R⁴, R⁵ and Q¹ are as defined above; and E¹ represents a bond or a methylene group.

- 17 -

The reaction is conveniently carried out by treating the compound V with a reducing agent such as lithium aluminium hydride in an appropriate solvent, e.g. tetrahydrofuran.

- 5 The intermediates of formula V above may suitably be prepared by reacting a compound of formula IV as defined above with a compound of formula VI:



(VI)

wherein R, R³, R⁴, R⁵ and E¹ are as defined above; and W represents a reactive carboxylate moiety.


- 20 Suitable values for the reactive carboxylate moiety W include esters, for example C₁₋₄ alkyl esters; acid anhydrides, for example mixed anhydrides with C₁₋₄ alkanolic acids; acid halides, for example acid chlorides; and acylimidazoles.

- 25 By way of example, the intermediates of formula VI above wherein W is an acid chloride moiety may be prepared by treating the corresponding carboxylic acid derivative with thionyl chloride in toluene. Similarly, the intermediates of formula VI wherein W is an acylimidazole moiety may be prepared by treating the
- 30 corresponding carboxylic acid derivative with 1,1'-carbonyldiimidazole. Alternatively, the reactive carboxylate moiety W may be obtained by treating the corresponding compound wherein W is carboxy with
- 35 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole hydrate, optionally in the presence of triethylamine; the

- 18 -

resulting activated carboxylate intermediate may then suitably be reacted in situ with the required compound of formula IV.

In a further procedure, the compounds according to the invention wherein Q represents a moiety of formula Qa in which the broken line represents a chemical bond may be prepared by a process which comprises reacting a compound of formula III as defined above with a compound of formula VII:



(VII)

wherein R¹ and R² are as defined above; followed by treatment of the resulting pyridinium salt with a reducing agent.

Reduction of the pyridinium salt is conveniently brought about by treatment with sodium borohydride in ethanol.

Where they are not commercially available, the starting materials of formula III, IV, VI and VII may be prepared by procedures analogous to those described in the accompanying Examples, or by standard methods well known from the art.

It will be appreciated that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further desired compound of formula I using techniques known from the art. For example, a compound of formula I wherein R is hydrogen initially obtained may be converted into a compound of formula I

- 19 -

wherein R represents C₁₋₆ alkyl by standard alkylation techniques, such as by treatment with an alkyl iodide, e.g. methyl iodide, typically under basic conditions, e.g. sodium hydride in dimethylformamide, or
5 triethylamine in acetonitrile. Moreover, a compound of formula I wherein Q represents a moiety of formula Qa in which the broken line represents a chemical bond initially obtained may be converted into the corresponding compound in which the broken line is absent
10 suitably by conventional catalytic hydrogenation techniques.

Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may
15 be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved
20 into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid, followed by
25 fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

30 During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in
35 Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in

- 20 -

Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

5 The following Examples illustrate the preparation of compounds according to the invention.

The compounds useful in this invention potentially inhibit [^3H]-spiperone binding to human dopamine D_4 receptor subtypes expressed in clonal cell lines.

10 [^3H]-Spiperone Binding Studies

Clonal cell lines expressing the human dopamine D_4 receptor subtype were harvested in PBS and then lysed in 10 mM Tris-HCl pH 7.4 buffer containing 5 mM MgSO_4 for 15 20 min on ice. Membranes were centrifuged at 50,000g for 15 min at 4°C and the resulting pellets resuspended in assay buffer (50 mM Tris-HCl pH 7.4 containing 5 mM EDTA, 1.5 mM CaCl_2 , 5 mM MgCl_2 , 5 mM KCl, 120 mM NaCl, and 0.1% ascorbic acid) at 20 mg/ml wet weight. Incubations were 20 carried out for 60 min at room temperature (22°C) in the presence of 0.05-2 nM [^3H]-spiperone or 0.2 nM for displacement studies and were initiated by addition of 20-100 μg protein in a final assay volume of 0.5 ml. The incubation was terminated by rapid filtration over GF/B 25 filters presoaked in 0.3% PEI and washed with 10 ml ice-cold 50 mM Tris-HCl, pH 7.4. Specific binding was determined by 10 μM apomorphine and radioactivity determined by counting in a LKB beta counter. Binding parameters were determined by non-linear least squares regression analysis, from which the inhibition constant 30 K_i could be calculated for each test compound.

The compounds of the accompanying Examples were tested in the above assay, and all were found to possess a K_i value for displacement of [^3H]-spiperone from the 35 human dopamine D_4 receptor subtype of below 1.5 μM .

EXAMPLE 12-(4-[2-Phenylethyl]piperidin-1-ylmethyl)benzimidazole

2-(Chloromethyl)benzimidazole (448mg, 2.64mmol) and potassium carbonate (729mg, 5.28mmol) were added to a solution of 4-(2-phenylethyl)piperidine (500mg, 2.64mmol) in dry DMF (20ml) under a nitrogen atmosphere and the mixture stirred at room temperature for 20 hours. The reaction was diluted with water (200ml) and extracted with ethyl acetate (3 x 100ml), the combined organic layers were washed with water (25ml) and brine (50ml), dried (MgSO₄) and evaporated *in vacuo* to give a brown oil which was triturated with toluene and recrystallised from methanol to give the *title compound* as a sandy solid (97.3mg, 12%), m.p. 170°C; (Found: C, 78.38; H, 7.79; N, 12.93. C₂₁H₂₅N₃·0.1 H₂O requires C, 78.51; H, 7.91; N, 13.08%); δ_H (DMSO-d₆) 1.22 (3H, m, piperidinyll H and CH₂CH₂Ph), 1.50 (2H, m, piperidinyll CH₂), 1.67 (2H, m, piperidinyll CH₂), 2.01 (2H, m, piperidinyll CH₂), 2.56-2.60 (2H, m, piperidinyll CH₂), 2.83 (2H, d, J 10.8Hz, CH₂-Ph), 3.67 (2H, s, N-CH₂Ar), 7.12-7.19 (5H, m, ArH), 7.24-7.28 (2H, m, ArH), 7.42 (1H, d, J 7.3Hz, ArH), 7.53 (1H, d, J 7.3Hz, ArH), and 12.20 (1H, brs, NH); m/z (CI⁺, NH₃) 320 (M+1)⁺.

Prepared in an analogous way were:

25

EXAMPLE 22-(1,2,3,4-Tetrahydroisoquinolin-2-ylmethyl)benzimidazole

M.p. 184-186°C (EtOAc); (Found: C, 76.60; H, 6.47, N, 15.76. C₁₇H₁₇N₃·0.2H₂O requires C, 76.49; H, 6.57; N, 15.74%); δ_H (DMSO-d₆) 2.50 (2H, t, J 1.8Hz, CH₂), 2.78 (2H, m, CH₂), 2.86 (2H, t, J 5.8Hz, CH₂), 3.65 (2H, s, N-CH₂), 3.90 (2H, s, N-CH₂),

7.01-7.17 (6H, m, ArH), 7.42 (1H, d, J 6.8Hz, ArH), 7.56 (1H, d, J 9.1Hz, ArH), and 12.32 (1H, brs, NH); m/z (CI⁺, NH₃) 264 (M+1)⁺.

EXAMPLE 3

5 2-(4-Phenyl-1,2,3,6-tetrahydropyridin-1-ylmethyl)
 benzimidazole

M.p. 253-255°C (MeOH); (Found: C, 77.72; H, 6.47; N, 14.48. C₁₉H₁₉N₃·0.25H₂O requires C, 77.65; H, 6.69; N, 14.30%); δ_H (DMSO-d₆) 2.82 (2H, brs, CH₂), 3.55 (2H, brs, CH₂), 4.01 (2H, brs, CH₂), 4.71 (2H, brs, CH₂-N), 6.21 (1H, brs, CH), 7.29-7.48 (5H, m, ArH), 7.48-7.51 (2H, m, ArH), 7.68-7.73 (2H, m, ArH), and 11.81 (1H, brs, NH); m/z (CI⁺, NH₃) 290 (M+1)⁺.

EXAMPLE 4

15 2-(4-Benzylpiperidin-1-ylmethyl)benzimidazole

M.p. 179-181°C (PhMe); (Found: C, 78.23; H, 7.36; N, 13.53; C₂₀H₂₃N₃ requires C, 78.65; H, 7.59; N, 13.76%); δ_H (CDCl₃) 1.27-1.38 (2H, m, piperidinyll H), 1.53-1.67 (3H, m, piperidinyll H), 2.13 (2H, t, J 11.8Hz, piperidinyll H), 2.55 (2H, d, J 6.8Hz, PhCH₂CH), 2.87 (2H, d, J 11.7Hz, piperidinyll H), 3.78 (2H, s, NCH₂Ar), 7.12-7.29 (9H, m, ArH), and 7.49 (1H, brs, NH); m/z (CI⁺, NH₃) 306 (M+1)⁺.

EXAMPLE 5

25 2-(1,2-Dihydroisoindol-2-ylmethyl)benzimidazole

M.p. 172-174°C (PhMe); (Found: C, 77.10; H, 5.99, N, 16.89; C₁₆H₁₅N₃ requires C, 77.08; H, 6.06; N, 16.85%); δ_H (CDCl₃) 4.05 (4H, s, isoindolinyll H), 4.24 (2H, s, NCH₂Ar), 7.15-7.25 (8H, m, ArH), and 7.53 (1H, brs, NH); m/z (CI⁺, NH₃) 250 (M+1)⁺.

EXAMPLE 65-Chloro-2-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)
benzimidazole

- 5 M.p. 204-206°C (PhMe); C, 68.38; H, 5.25; N, 13.92.
C₁₉H₁₆ClN₃ requires C, 68.57; H, 5.42; N, 14.11%; δ_H (CDCl₃)
2.99-3.03 (4H, m, 2 x tetrahydroisoquinolyl CH₂), 3.85 (2H, s,
tetrahydroisoquinolyl CH₂), 4.13 (2H, s, NCH₂Ar), 7.00 (1H, d,
J 8.6Hz, ArH), 7.12-7.26 (5H, m, ArH), 7.49 (1H, d, J 12.3Hz,
10 ArH), and 7.57 (1H, brs, NH); m/z (CI⁺, NH₃) 298 (M+1)⁺.

EXAMPLE 75-Methoxy-2-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)
benzimidazole dihydrochloride

- 15 M.p. 212-215°C (MeOH/Et₂O); (Found: C, 59.14; H, 5.69; N,
11.13. C₁₈H₁₉N₃O.2HCl requires C, 59.02; H, 5.77; N, 11.47%); δ_H
(DMSO-d₆) 3.13 (2H, brs, tetrahydroisoquinolyl CH₂), 3.53 (2H,
brs, tetrahydroisoquinolyl CH₂), 3.84 (3H, s, OCH₃), 4.44 (2H, brs,
tetrahydroisoquinolyl CH₂), 4.71 (2H, s, NCH₂Ar), 7.04 (1H, dd, J
20 9.0, 2.3Hz, ArH), 7.16-7.27 (5H, m, ArH), and 7.65 (1H, d, J 9.0Hz,
ArH); m/z (CI⁺, NH₃), 294 (M+1)⁺.

EXAMPLE 8

- 25 2-(4-[3-Phenylpropyl]-1,2,3,6-tetrahydropyridin-1-ylmethyl)
benzimidazole

A mixture of 2-(chloromethyl)benzimidazole (2.48g,
14.9mmol) and 4-(3-phenylpropyl)pyridine (15ml) was stirred at

140°C under a nitrogen atmosphere for ten minutes. The reaction mixture was allowed to cool and the resultant solid triturated with acetonitrile (10ml). The mixture was diluted with ethyl acetate (10ml), the solid collected by filtration and washed with acetonitrile/ethyl acetate to afford the intermediate pyridinium salt (4.85g, 85%), as a tan solid.

A portion of this solid (2.51g, 6.90mmol) was dissolved in ethanol (70ml) and sodium borohydride (1.04g, 27.5mmol) added portionwise to the solution over a five minute period. The reaction mixture was stirred at room temperature under a nitrogen atmosphere for thirty minutes followed by addition of acetic acid (approx. 3ml) and further stirring for ten minutes. The precipitated solid was collected and the filtrate concentrated *in vacuo*. Saturated aqueous potassium carbonate (100ml) was added to the residue and the mixture extracted with ethyl acetate (2 x 100ml). The extracts were washed with brine (50ml), combined, dried (MgSO₄) and evaporated to an amber oil which crystallised on standing. Recrystallisation from ethyl acetate gave the *title compound* (1.52g, 66%) as a white crystalline solid, m.p. 131-132°C; (Found: C, 79.85; H, 7.78; N, 12.71. C₂₂H₂₅N₃ requires C, 79.72; H, 7.60; N, 12.68%); δ_H (DMSO-d₆) 1.67 (2H, m, CH₂CH₂CH₂Ph), 1.96 (2H, t, J 7.5Hz, CH₂CH₂CH₂Ph), 2.04 (2H, br s, tetrahydropyridinyl CH₂), 2.56 (4H, m, CH₂CH₂CH₂Ph and tetrahydropyridinyl CH₂), 2.96 (2H, br s, tetrahydropyridinyl CH₂), 3.76 (2H, s, N-CH₂Ar), 5.37 (1H, br s, -CH=), 7.14 (5H, m, ArH), 7.27 (2H, m, ArH), 7.42 (1H, d, J 7Hz, ArH), 7.54 (1H, d, J 7Hz, ArH), and 12.28 (1H, br s, NH); m/z (CI⁺, NH₃) 332 (M+1)⁺.

30

Prepared in an analogous manner was:

EXAMPLE 9

5 2-(4-Phenylmethyl-1.2.3.6-tetrahydropyridin-1-ylmethyl)
 benzimidazole

 M.p. 177-178°C (dec.) (EtOAc); (Found: C, 79.18; H, 6.72; N,
 13.54. $C_{20}H_{21}N_3$ requires C, 79.17; H, 6.98; N, 13.85%); δ_H
10 (DMSO- d_6) 1.98 (2H, br s, tetrahydropyridinyl CH_2), 2.54 (2H, t,
 J 5.7Hz, tetrahydropyridinyl CH_2), 3.26 (2H, s, CH_2Ph), 3.75 (2H,
 s, $N-CH_2Ar$), 5.42 (1H, br s, $CH=CR$), 7.16 (5H, m, ArH), 7.27 (2H,
 m, ArH), 7.40 (1H, br d, J 6.9Hz, ArH), 7.53 (1H, br d, J 6.9Hz,
 ArH), and 12.26 (1H, br s, NH); m/z (CI^+ , NH_3) 304 ($M+1$) $^+$.

15

EXAMPLE 10

2-(4-[2-Phenylethyl]-1.2.3.6-tetrahydropyridin-1-ylmethyl)
 benzimidazole

20

 M.p. 177-179°C (PhMe); (Found: C, 79.54; H, 7.19; N, 13.07.
 $C_{21}H_{23}N_3$ requires C, 79.56; H, 7.30; N, 13.24%); δ_H ($CDCl_3$) 2.18
 (2H, br s, CH_2), 2.28-2.32 (2H, m, CH_2), 2.69-2.76 (4H, m, 2 x
 CH_2), 3.09 (2H, br s, CH_2), 3.91 (2H, s, $ArCH_2N$), 5.42 (1H, br s,
25 $CH=CR$), 7.17-7.31 (8H, m, ArH), and 7.57 (2H, br s, $ArH+NH$);
 m/z (CI^+ , NH_3) 318 ($M+1$) $^+$.

EXAMPLE 112-(4-[2-Phenylethynyl]-1,2,3,6-tetrahydropyridin-1-ylmethyl)
benzimidazole dihydrochloride

5

M.p. 244°C (dec.) (MeOH/Et₂O); (Found: C, 64.96; H, 5.47; N, 11.28. C₂₁H₂₁Cl₂N₃ requires C, 65.29; H, 5.48; N, 10.88%); δ_H (DMSO-d₆) 2.60 (2H, br s, CH₂), 3.37-3.39 (2H, m, CH₂), 3.88 (2H, br s, CH₂), 4.65 (2H, s, CH₂N), 6.20 (1H, s, CH=CR), 7.39-7.47 (7H, m, ArH), and 7.73-7.76 (2H, m, ArH); m/z (Cl⁺, NH₃) 314 (M+1)⁺.

10

EXAMPLE 122-(4-Benzoyloxy-1,2,3,6-tetrahydropyridin-1-ylmethyl)
benzimidazole

15

Step 1: 4-Benzoyloxy-1,2,3,6-tetrahydropyridine

20

To a suspension of sodium hydride (80% dispersed in oil, 876mg, 29.2mmol) in DMSO (10ml) was added benzyl alcohol (3ml, 29.2mmol) and the mixture stirred at room temperature for 1 hour. To this was added 4-chloropyridine (3.3g, 29.2mmol) and the reaction stirred at room temperature overnight. The precipitated sodium chloride was removed by filtration and the filtrate diluted with water (100ml) and extracted with ether (3 x 120ml). The combined organic layers were dried (MgSO₄) and evaporated *in vacuo* to yield the *title compound* as an oil (4.8g, 95%); δ_H (CDCl₃) 5.11 (2H, s, PhCH₂O), 6.87 (2H, d, J 6.3Hz, 3-H, 5-H), 7.29-7.42 (5H, m, Ph), and 8.42 (2H, d, J 6.3Hz, 2-H, 6-H).

25
30

Step 2: 2-(4-Benzoyloxy-1,2,3,6-tetrahydropyridin-1-ylmethyl)
benzimidazole

Prepared from 4-benzoyloxy pyridine and 2-(chloromethyl)
5 benzimidazole in an analogous manner to that described
previously. M.p. 170-172°C (PhMe); (Found: C, 75.19; H, 6.45;
N, 13.02. $C_{20}H_{21}N_3O$ requires C, 75.21; H, 6.63; N, 13.16%). δ_H
($CDCl_3$) 2.35 (2H, br s, tetrahydropyridinyl 3- CH_2), 2.81 (2H, t,
J 5.6Hz, tetrahydropyridinyl 2- CH_2), 3.21 (2H, br s,
10 tetrahydropyridinyl 6- CH_2), 3.98 (2H, s, NCH_2Ar), 4.75 (1H, br s,
tetrahydropyridinyl 5-CH), 4.81 (2H, s, $PhCH_2O$), 7.22-7.27 (3H,
m, ArH), 7.31-7.37 (6H, m, ArH), and 7.56 (1H, br s, NH);
m/z (CI^+ , NH_3), 336 ($M+NH_4$)⁺.

15

EXAMPLE 13

2-(4-[3-Phenylpropyl]piperidin-1-ylmethyl)benzimidazole

A mixture of 2-(4-[3-phenylpropyl]-1,2,3,6-tetrahydropyridin-1-
20 ylmethyl)benzimidazole (1.01g, 3.05mmol) and platinum (IV) oxide
hydrate (56mg) in ethyl acetate (75ml) was hydrogenated on a Parr
apparatus (30psi maximum) for 70 minutes. Fresh catalyst was added
(40mg) and the mixture hydrogenated for a further 2.5h. The mixture
was filtered and evaporated to dryness. Flash chromatography eluting
25 with 7.5% methanol in dichloromethane followed by recrystallisation
from ethyl acetate/petrol (60-80°C) gave the *title compound* (0.52g,
52%) as a white solid, m.p. 140-141°C; (Found: C, 79.25; H, 8.07; N,
12.39. $C_{22}H_{27}N_3$ requires C, 79.24; H, 8.16; N, 12.60%); δ_H (DMSO- d_6)
1.19 (5H, m, 2 x CH_2 + piperidinyl CH), 1.57 (4H, m, 2 x CH_2), 2.02
30 (2H, m, CH_2), 2.55 (2H, m, piperidinyl CH_2), 2.81 (2H, m, piperidinyl
 CH_2), 3.66 (2H, s, CH_2N), 7.15 (5H, m, ArH), 7.26 (2H, m, ArH), 7.43
(1H, br d, ArH), 7.51 (1H, br d, ArH), and 12.16 (1H, br s, NH); m/z
(CI^+ , NH_3) 334 ($M+1$)⁺.

EXAMPLE 142-(4-Benzylloxypiperidin-1-ylmethyl)benzimidazole

5

Step 1: 1-(tert-Butoxycarbonyl)-4-benzylloxypiperidine

Sodium hydride, 80% dispersion in oil (0.14g, 4.8mmol) was added to a solution of 1-(tert-butoxycarbonyl)-4-hydroxypiperidine (1.0g, 4.8mmol) [prepared from 4-hydroxypiperidine and di-tert-butyl dicarbonate] in dimethylformamide (30ml) and the mixture stirred for 30 minutes. Benzyl bromide (0.68ml, 5.7mmol) was added and the reaction mixture stirred overnight. The mixture was poured into water and extracted with dichloromethane. The extracts were washed with water and brine, dried (MgSO₄) and the residue after evaporation purified by flash chromatography eluting with 0-20% ethyl acetate in hexane to give 1-(tert-butoxycarbonyl)-4-benzylloxypiperidine (1.1g, 94%); δ_H (CDCl₃) 1.39 (9H, s, C(CH₃)₃), 1.82 (2H, m, piperidiny H), 3.04 (2H, m, piperidiny H), 3.59 (3H, m, piperidiny H), 4.51 (2H, s, OCH₂Ph), 7.24-7.39 (5H, m, PhH).

Step 2: 2-(4-Benzylloxypiperidin-1-ylmethyl)benzimidazole

Trifluoroacetic acid (5ml) was added to a solution of 1-(tert-butoxycarbonyl)-4-benzylloxypiperidine (2.08g, 7.14mmol) in dichloromethane (20ml) and the solution stirred for 30 minutes at room temperature under nitrogen. The solution was concentrated *in vacuo*, the residue was redissolved in dichloromethane (20ml) and treated with trifluoroacetic acid (20ml). The solution was stirred for 30 minutes, partially evaporated and poured into saturated aqueous potassium carbonate solution (50ml). The mixture was diluted with water (50ml) and extracted with dichloromethane (2 x 100ml). The

combined extracts were dried (MgSO_4) and concentrated *in vacuo* to give crude 4-benzyloxypiperidine (1.29g), as an amber oil. A portion of this material (0.59g, 3.08mmol) was dissolved in dimethylformamide (15ml). Potassium carbonate (0.85g, 6.15mmol) and 2-(chloromethyl) benzimidazole (0.46g, 2.76mmol) were added to the solution and the mixture stirred at room temperature, under nitrogen, overnight. The reaction mixture was poured into water (150ml) and extracted with ethyl acetate (2 x 100ml). The extracts were washed with brine (100ml), combined, dried (MgSO_4) and the residue after evaporation purified by flash chromatography, eluting with 7.5% methanol in dichloromethane, to give the *title compound* (0.26g, 30%) as a pale yellow solid. Recrystallisation from ethyl acetate afforded very pale yellow needles, m.p. 190.5-191°C; (Found: C, 74.83; H, 7.17; N, 13.00. $\text{C}_{20}\text{H}_{23}\text{N}_3\text{O}$ requires C, 74.74; H, 7.21; N, 13.07%); δ_{H} ($\text{DMSO}-d_6$) 1.56 (2H, m, piperidiny l H), 1.88 (2H, m, piperidiny l H), 2.21 (2H, m, piperidiny l H), 2.74 (2H, m, piperidiny l H), 3.40 (1H, m, piperidiny l CH-O), 3.69 (2H, s, CH_2N), 4.49 (2H, s, OCH_2Ph), 7.12 (2H, m, ArH), 7.27 (5H, m, ArH), 7.48 (2H, br s, ArH), and 12.23 (1H, br s, NH); m/z (Cl^+ , NH_3) 322 ($\text{M}+\text{H}$)⁺.

EXAMPLE 15

2-(4-[3-Phenylpropylidenel]piperidin-1-ylmethyl)benzimidazole

Step 1: 4-(3-Phenylpropylidene)piperidine

n-Butyl lithium (2.5M in hexanes, 14ml, 35mmol) was carefully added to a cold ($<0^\circ\text{C}$) suspension of 3-phenylpropyltriphenylphosphonium bromide (18.7g, 40.5mmol) in THF (100ml) under a nitrogen atmosphere at such a rate that the temperature did not exceed 0°C . The orange solution was stirred at $<0^\circ\text{C}$ for 30 minutes before a solution of 1-(*tert*-butyloxycarbonyl)-4-piperidone (5.0g, 27mmol) was added as a solution in THF (20ml) at such a rate that the temperature did not exceed 0°C . The

mixture was stirred at 0°C for 1 hour and then allowed to warm to room temperature before adding water (20ml). The mixture was concentrated *in vacuo* and the residue extracted into dichloromethane (3 x 100ml). The combined organics were washed with water (20ml) and brine (20ml), dried (MgSO₄) and evaporated *in vacuo* to give a yellow oil. The oil was purified by column chromatography on silica eluting with 10% EtOAc/petrol 60/80 to give a clear oil. The oil was dissolved in dichloromethane (30ml) and treated with trifluoroacetic acid (20ml) and the mixture stirred at room temperature for 1.5h. The solution was evaporated *in vacuo* and azeotroped with toluene (2 x 10ml). The residue was dissolved in EtOAc (20ml) and washed with sodium carbonate (saturated, 2 x 10ml), water (10ml) and brine (10ml), dried (MgSO₄) and evaporated *in vacuo* to give 4-(3-phenylpropylidene) piperidine as a pale oily solid (4.92g, 90%).

Step 2: 2-(4-[3-Phenylpropylidene]piperidin-1-ylmethyl) benzimidazole

Prepared as described before, m.p. 163-165°C (EtOAc); (Found: C, 79.99; H, 7.52; N, 12.67. C₂₂H₂₅N₃ requires C, 79.72; H, 7.60; N, 12.68%); δ_H (CDCl₃) 2.17-2.23 (4H, m, 2 x piperidiny CH₂), 2.28-2.38 (4H, m, aliphatic H), 2.51 (2H, t, J 5.6Hz, aliphatic H), 2.64 (2H, t, J 7.5Hz, CH₂CH₂Ph), 3.79 (2H, s, CH₂-N), 5.21 (1H, t, J 7.3Hz, C=CH), 7.14-7.21 (3H, m, ArH), 7.22-7.28 (4H, m, ArH), and 7.40-7.60 (2H, br s, ArH); m/z (CI⁺, NH₃) 332 (M+1)⁺.

EXAMPLE 16(E)-2-(4-[2-Phenylethenyl]-1,2,3,6-tetrahydropyridin-1-ylmethyl)benzimidazole

5

A solution of 4-styrylpyridine (4.0g, 22.1mmol) and 2-chloromethylbenzimidazole (3.7g, 22.1mmol) in dimethylformamide (20ml) was heated at 110-120°C under a nitrogen atmosphere for 1.5 hours. The mixture was cooled to room temperature, diluted with ethanol (380ml) and carefully treated with sodium borohydride (880mg, 23.2mmol). The mixture was stirred at room temperature for 2 hours, then heated at reflux for 1 hour before stirring at room temperature overnight. The ethanol was evaporated *in vacuo* and the residue partitioned between ethyl acetate (100ml) and sodium carbonate (half saturated, 100ml). The phases were separated and the aqueous was extracted with ethyl acetate (2 x 100ml). The combined organics were washed with water (50ml) and brine (50ml), dried (MgSO₄) and evaporated *in vacuo* to give a reddish gummy residue which was purified by flash chromatography (eluting with 5% methanol in dichloromethane) to give a yellow gummy solid. The gum was triturated with ethyl acetate and recrystallised from ethyl acetate to give the *title compound* as a mustard solid (912mg, 13%). M.p. 225-227°C (EtOAc); (Found: C, 79.74; H, 6.89; N, 13.47. C₂₁H₂₁N₃ requires C, 79.97; H, 6.71; N, 13.32%); δ_H (DMSO-d₆) 2.37 (2H, br s, tetrahydropyridinyl CH₂), 2.69 (2H, t, J 5.6Hz, tetrahydropyridinyl CH₂), 3.17 (2H, br s, tetrahydropyridinyl CH₂), 3.83 (2H, s, NCH₂Ar), 5.91 (1H, s, CH=CR), 6.48 (1H, d, J 16.2Hz, CHCHPh), 6.91 (1H, d, J 16.2Hz, CHPh), 7.13-7.22 (3H, m, ArH), 7.29-7.33 (2H, m, ArH), 7.42-7.47 (3H, m, ArH), 7.54 (1H, m, ArH), and 12.31 (1H, br s, NH); m/z (CI⁺, NH₃) 316 (M+1)⁺.

10

15

20

25

30

EXAMPLE 171-Methyl-2-(4-(E)-2-phenylethenyl-1,2,3,6-tetrahydropyridin-1-ylmethyl)benzimidazole

5

The *title compound* was prepared by treatment of 2-chloromethyl-1-methylbenzimidazole (prepared using the procedure of M.A. Phillips, J. Chem. Soc., 1928, 2393) in a manner analogous to Example 16.

10

M.p. 188-190°C (MeOH/Et₂O); (Found: C, 58.69; H, 6.50; N, 9.15. C₂₂H₂₃N₃·2HCl·2.5H₂O requires C, 59.06; H, 6.76; N, 9.39%); δ_H (DMSO-d₆) 2.45-2.56 (2H, m, tetrahydropyridinyl CH₂), 2.72 (2H, m, tetrahydropyridinyl CH₂), 4.01 (3H, s, CH₃), 4.08 (2H, br s, tetrahydropyridinyl CH₂), 4.83 (2H, s, NCH₂Ar), 5.94 (1H, br s, tetrahydropyridinyl CH=CR), 6.63 (1H, d, J 16.3Hz, CH=CH-Ph), 6.99 (1H, d, J 16.3Hz, CH=CH-Ph), 7.23-7.53 (7H, m, ArH), and 7.77 (2H, d, J 7.7Hz, ArH); m/z (CI⁺, NH₃) 330 (M+1)⁺.

15

20

EXAMPLE 182-(4-[Benzothiophen-2-yl]-1,2,3,6-tetrahydropyridin-1-ylmethyl)benzimidazole

25

Step 1: 1-Benzyl-4-(benzothiophen-2-yl)-1,2,3,6-tetrahydropyridine

30

To a solution of benzothiophene (3g, 22.4mmol) in anhydrous tetrahydrofuran (50ml) at -10°C under nitrogen was added n-butyllithium (9.83ml of a 2.5M solution in toluene), the mixture was left to warm to room temperature and stirred for 1 hr. The reaction mixture was cooled to -40°C, 1-benzyl-4-piperidone (4.23g, 22.4mmol) added, the mixture left to warm to room

temperature and stirred for 14 hr. The reaction mixture was concentrated *in vacuo* and trifluoroacetic acid (10ml) added. This mixture was stirred at room temperature for 14 hr then concentrated *in vacuo*. The product was extracted into
5 dichloromethane (3 x 100ml) from aqueous potassium carbonate. The organic layer was washed with water (1 x 50ml), brine (1 x 50ml), then dried (MgSO₄). After concentration of the extracts the crude product was purified using silica gel column chromatography to yield the *title compound* (4.2g, 68%) as a
10 colourless oil; δ_H (CDCl₃) 2.64 (2H, m, tetrahydropyridinyl CH₂), 2.74 (2H, m, tetrahydropyridinyl CH₂), 3.18 (2H, m, tetrahydropyridinyl CH₂), 3.65 (2H, s, PhCH₂N), 6.18 (1H, m, CH=C), 7.11 (1H, s, benzothiophene 3-H), and 7.24-7.73 (9H, m, ArH).

15

Step 2: 4-(Benzothiophen-2-yl)-1,2,3,6-tetrahydropyridine hydrochloride

To a solution of 1-benzyl-4-(benzothiophen-2-yl)-1,2,3,6-tetrahydropyridine (4g, 13.1mmol) in anhydrous dichloromethane
20 (50ml) at 0°C under nitrogen was added 2-chloroethylchloroformate (1.84ml, 17.0mmol) and the mixture stirred for 1 hr. The reaction mixture was concentrated *in vacuo*, methanol (20ml) added and heated to reflux for 1 hr. After
25 cooling the *title compound* was collected by filtration (2.2g, 67%), m.p. 269°C (dec.).

30

Step 3: 2-(4-Benzothiophen-2-yl)-1,2,3,6-tetrahydropyridin-1-ylmethylbenzimidazole

The *title compound* was prepared in a analogous manner to Example 1 using 4-(benzothiophen-2-yl)-1,2,3,6-tetrahydropyridine hydrochloride and 2-

chloromethylbenzimidazole, m.p. 241°C (dec.); (Found: C, 72.44; H, 5.41; N, 11.83. $C_{12}H_{19}N_3S \cdot 0.1H_2O$ requires C, 72.63; H, 5.57; N, 12.10%); δ_H (DMSO- d_6) 2.62 (2H, br s, tetrahydropyridinyl CH_2), 2.77 (2H, m, tetrahydropyridinyl CH_2), 3.24 (2H, d, J 2.8Hz, tetrahydropyridinyl CH_2), 3.87 (2H, s, NCH_2Ar), 6.23 (1H, br s, $CH=CR$), 7.10-7.42 (5H, m, ArH), 7.45 (1H, d, J 8Hz, ArH), 7.74 (1H, d, J 8Hz, ArH), 7.76 (1H, dd, J 8, 2Hz, ArH), 7.86 (1H, dd, J 8, 2Hz, ArH), and 12.32 (1H, br s, NH); m/z (Cl^+ , NH_3) 346 ($M+1$) $^+$.

EXAMPLE 19

2-(4-[Benzofuran-2-yl]-1,2,3,6-tetrahydropyridin-1-ylmethyl)benzimidazole

M.p. 202-204°C (PhMe); (Found: C, 76.45; H, 5.51; N, 11.73. $C_{21}H_{19}N_3O$ requires C, 76.58; H, 5.81; N, 12.76%); δ_H (DMSO- d_6) 2.59 (2H, br s, tetrahydropyridinyl CH_2), 2.85 (2H, t, J 5.7Hz, tetrahydropyridinyl CH_2), 3.35 (2H, br s, tetrahydropyridinyl CH_2), 3.99 (2H, s, NCH_2Ar), 6.50 (1H, br s, tetrahydropyridinyl 5-CH), 6.56 (1H, s, 2'-H), 7.16-7.27 (6H, m, ArH), 7.43 (1H, d, J 7.9Hz, ArH), 7.52 (1H, d, J 7.3Hz, ArH), and 7.62 (1H, br s, NH); m/z (Cl^+ , NH_3) 330 ($M+1$) $^+$.

EXAMPLE 20

2-(4-(E)-(2-(Thien-2-yl)ethenyl)-1,2,3,6-tetrahydropyridin-1-ylmethyl)benzimidazole

M.p. 180-185°C (dec.) (PhMe); (Found: C, 69.97; H, 5.70; N, 12.45. $C_{19}N_3S$ requires C, 70.99; H, 5.96; N, 13.07%); δ_H (DMSO- d_6) 2.44 (2H, br s, tetrahydropyridinyl CH_2), 2.80 (2H, t, J 5.8Hz, tetrahydropyridinyl CH_2), 3.26 (2H, br s,

tetrahydropyridinyl CH₂), 3.96 (2H, s, NCH₂Ar), 5.79 (1H, br s, tetrahydropyridinyl 5-CH), 6.62 (2H, s, CH=CHAr), 6.95-6.97 (2H, m, ArH), 7.13-7.15 (1H, m, ArH), 7.22-7.27 (4H, m, ArH), and 7.62 (1H, br s, NH); m/z (CI⁺, NH₃) 322 (M+1)⁺.

5

EXAMPLE 21

2-(4-(E)-(2-(Thien-3-yl)ethenyl)-1.2.3.6-tetrahydropyridin-1-ylmethyl)benzimidazole

10

M.p. 216-218°C (PhMe); (Found: C, 71.03; H, 5.80; N, 12.97. C₁₉H₁₉N₃S requires C, 70.99; H, 5.96; N, 13.07%); δ_H (DMSO-d₆) 2.44 (2H, br s, tetrahydropyridinyl CH₂), 2.80 (2H, t, J 5.8Hz, tetrahydropyridinyl CH₂), 3.25 (2H, br s, tetrahydropyridinyl CH₂), 3.95 (2H, s, NCH₂Ar), 5.78 (1H, br s, tetrahydropyridinyl 5-CH), 6.50 (1H, d, J 16.1Hz, CH=CHAr), 6.65 (1H, d, J 16.1Hz, CH=CHAr), 7.15 (1H, d, J 1.7Hz, ArH), and 7.22-7.29 (6H, m, ArH); m/z (CI⁺, NH₃) 322 (M+1)⁺.

15

20

EXAMPLE 22

2-(4-(E)-(2-(Furan-2-yl)ethenyl)-1.2.3.6-tetrahydropyridin-1-ylmethyl)benzimidazole

25

Step 1: 1-(4-Pyridyl)-2-(furan-2-yl)ethene

A solution of 4-methylpyridine (15g, 0.16mol) in acetic anhydride (100ml) was treated with 2-furaldehyde (15.5g, 0.16mol) and the mixture heated at reflux for 16 hr. The solvent was evaporated to give a black oil which was treated with water (30ml) and stirred for 30 mins at room temperature. Ethyl acetate (150ml) and saturated sodium carbonate (100ml) were then added and the stirring continued for 30 min. The solvents

30

were decanted to leave a black oily residue which was retained (A). From the decanted solvents the organic phase was separated, dried (Na_2SO_4) and evaporated to give a black oil (B). The oily residue (A) was dissolved in dichloromethane (150ml), washed
5 with saturated sodium carbonate solution (100ml), dried (Na_2SO_4) and evaporated to give a black oil which was combined with oil (B). The mixture was chromatographed on silica gel with a gradient of ethyl acetate in hexane (50% - 100%) as eluant to afford the *title compound* as a brown solid (9.8g, 36%); δ_{H}
10 (DMSO- d_6) 6.58-6.64 (1H, m, furanyl H), 6.66-6.72 (1H, m, furanyl H), 6.96 (1H, d, J 17.5Hz, $\text{CH}=\text{CH}$), 7.42 (1H, d, J 17.5Hz, $\text{CH}=\text{CH}$), 6.50-6.58 (2H, m, pyridyl H), 7.78-7.82 (1H, m, furanyl H), and 8.50-8.51 (2H, m, pyridyl H).

15 Step 2: 2-(4-(E)-(2-Furan-2-yl)ethenyl)-1,2,3,6-tetrahydropyridin-1-ylmethyl)benzimidazole

A solution of 1-(4-pyridyl)-2-(furan-2-yl)ethene (625mg, 3.65mmol) in anhydrous dimethylformamide (10ml) was treated
20 with 2-chloromethylbenzimidazole (671mg, 4.02mmol). The reaction mixture was stirred at reflux for two hours. The solvent was evaporated and the residue redissolved in absolute ethanol (50ml). Sodium borohydride (174mg, 4.56mmol) was added and the mixture stirred at reflux for 40 mins. The solvent was
25 evaporated and the residue partitioned between dichloromethane and water. The organic phase was separated, dried (MgSO_4) and evaporated. The residue was chromatographed on silica gel using 97:3:1 dichloromethane/methanol/ammonia as eluant to afford the *title compound* (148mg, 13%) as a colourless solid, m.p. 193-
30 195°C; (Found: C, 73.37; H, 6.14; N, 13.15. $\text{C}_{19}\text{H}_{19}\text{N}_3\text{O} \cdot 0.25\text{H}_2\text{O}$ requires C, 73.64; H, 6.34; N, 13.56%); δ_{H} (DMSO- d_6) 2.28-2.36 (2H, m, tetrahydropyridinyl CH_2), 2.67 (2H, t, J 5.7Hz, tetrahydropyridinyl CH_2), 3.14-3.22 (2H, m, tetrahydropyridinyl

CH₂), 3.82 (2H, s, NCH₂Ar), 5.85-5.94 (1H, m, tetrahydropyridinyl CH), 6.34 (1H, d, J 16.1Hz, CH=CH), 6.42-6.45 (1H, m, furan 4-H), 6.47-6.52 (1H, m, furan 3-H), 6.68 (1H, d, J 16.2Hz, CH=CH), 7.10-7.18 (2H, m, 5-H and 6-H), 7.42 (1H, d, J 6.9Hz, 7-H), 7.55 (1H, d, J 7.0Hz, 4-H), 7.59 (1H, d, J 1.3Hz, furan 5-H), and 12.30 (1H, s, NH); m/z (CI⁺, NH₃) 306 (M+1)⁺.

EXAMPLE 23

10 2-(4-(E)-(2-(5-Methylfuran-2-yl)ethenyl)-1,2,3,6-tetrahydropyridin-1-ylmethyl)benzimidazole

15 1-(4-Pyridyl)-2-(5-methylfuran-2-yl)ethene was prepared in the same manner as 1-(4-pyridyl)-2-(furan-2-yl)ethene described in Example 22, Step 1.

20 A solution of 4-[2-(5-methylfuran-2-yl)ethenyl]pyridine (1.0g, 5.41mmol) in anhydrous dimethylformamide (20ml) was treated with 2-chloromethylbenzimidazole (1.0g, 5.95mmol). The reaction was stirred at reflux for two hours. The solvent was evaporated and the residue redissolved in absolute ethanol (50ml). Sodium borohydride (251mg, 6.76mmol) was added and the mixture stirred at reflux for 40 mins. The solvent was evaporated and the residue partitioned between dichloromethane and water. The organic phase was separated, dried (MgSO₄) and evaporated. The residue was chromatographed on silica gel using 97:3:1 dichloromethane/methanol/ammonia as eluant to afford the *title compound* (500mg, 30%) as a pale lemon solid, m.p. 191-193°C; (Found: C, 75.33; H, 6.32; N, 13.17. C₂₀H₂₁N₃O requires C, 75.21; H, 6.63; N, 13.16); δ_H (DMSO-d₆) 2.25-2.35 (5H, m, CH₃ and tetrahydropyridinyl CH₂), 2.66 (2H, t, J 5.7Hz, tetrahydropyridinyl CH₂), 3.14-3.20 (2H, m, tetrahydropyridinyl CH₂), 3.82 (2H, s, NCH₂Ar), 5.82-5.88 (1H, m, tetrahydropyridinyl

CH), 6.06-6.10 (1H, m, furan 4-H), 6.22-6.30 (2H, m, CH=CH and furan 3-H), 6.58 (1H, d, J 16.1Hz, CH=CH), 7.05-7.20 (2H, m, 5-H and 6-H), 7.38-7.60 (2H, m, 4-H and 7-H), and 12.29 (1H, s, NH); m/z (CI⁺, NH₃) 320 (M+1)⁺.

5

EXAMPLE 24

(E)-2-(4-[2-(3-Methoxyphenyl)ethenyl]-1,2,3,6-tetrahydropyridin-1-yl)methyl benzimidazole

10

M.p. 202-204°C (EtOAc); (Found: C, 76.20; H, 6.48; N, 11.83. C₂₂H₂₃N₃O requires C, 76.49; H, 6.71; N, 12.16%); δ_H (CDCl₃) 2.51 (2H, br s, tetrahydropyridinyl CH₂), 2.84-2.88 (2H, m, tetrahydropyridinyl CH₂), 3.31 (2H, br s, tetrahydropyridinyl CH₂), 3.82 (3H, s, OCH₃), 4.02 (2H, s, ArCH₂N), 5.82 (1H, br s, tetrahydropyridinyl 5-H), 6.46 (1H, d, J 16.1Hz, CH=CH), 6.76-6.80 (2H, m, ArH and CH=CH), 6.94 (1H, d, J 2.2Hz, 2'-H), 7.01 (1H, d, J 7.8Hz, ArH), 7.21-7.28 (3H, m, ArH), and 7.58 (2H, br s, ArH); m/z (CI⁺, NH₃) 346 (M+1)⁺.

15

20

EXAMPLE 25

2-(4-Phenoxymethyl-1,2,3,6-tetrahydropyridin-1-yl)methyl benzimidazole

25

M.p. 184°C (dec.) (PhMe); (Found: C, 75.14; H, 6.47; N, 12.92. C₂₀H₂₁N₃O requires C, 75.21; H, 6.63; N, 13.16%); δ_H (CDCl₃) 2.32 (2H, br s, tetrahydropyridinyl CH₂), 2.77 (2H, t, J 5.8Hz, tetrahydropyridinyl CH₂), 3.17 (2H, br s, tetrahydropyridinyl CH₂), 3.95 (2H, s, ArCH₂N), 4.44 (2H, s, CH₂OAr), 5.81 (1H, br s, tetrahydropyridinyl 5-H), 6.91-6.98 (3H, m, ArH), 7.18-7.31 (4H, m, ArH), and 7.58 (2H, br s, ArH); m/z (CI⁺, NH₃) 320 (M+1)⁺.


30

- 39 -

CLAIMS:

1. A compound of formula I, or a salt or
prodrug thereof:

5




(I)


15 wherein

E represents $-\text{CH}_2-$ or $-\text{CH}_2\text{CH}_2-$;R represents hydrogen or C_{1-6} alkyl;


Q represents a moiety of formula Qa, Qb or Qc:



(Qa)



(Qb)



(Qc)

in which the broken line represents an optional chemical
bond;


R^1 represents hydrogen, or an optionally
30 substituted C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkenyl, C_{2-6}
alkynyl, aryl, aryl(C_{1-6})alkyl, aryl(C_{1-6})alkoxy,
aryl(C_{2-6})alkenyl, aryl(C_{2-6})alkynyl, C_{3-7}
heterocycloalkyl(C_{1-6})alkyl, heteroaryl,
heteroaryl(C_{1-6})alkyl, heteroaryl(C_{2-6})alkenyl or
35 heteroaryl(C_{2-6})alkynyl group;

- 40 -

- R^2 represents an optionally substituted C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{3-7} heterocycloalkyl(C_{1-6})alkyl group; or aryl, aryl(C_{1-6})alkyl, aryloxy(C_{1-6})alkyl, aryl(C_{1-6})alkoxy, aryl(C_{2-6})alkenyl, aryl(C_{2-6})alkynyl, heteroaryl, heteroaryl(C_{1-6})alkyl, heteroaryl(C_{2-6})alkenyl or heteroaryl(C_{2-6})alkynyl, any of which groups may be optionally substituted on the aromatic moiety;
- R^3 , R^4 and R^5 independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, $-OR^a$, $-SR^a$, $-SOR^a$, $-SO_2R^a$, $-SO_2NR^aR^b$, $-NR^aR^b$, $-NR^aCOR^b$, $-NR^aCO_2R^b$, $-COR^a$, $-CO_2R^a$ or $-CONR^aR^b$;
- Z represents $-CH_2-$ or $-CH_2CH_2-$;
- R^6 represents hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, aryl, aryl(C_{1-6})alkyl or halogen; and
- R^a and R^b independently represent hydrogen, hydrocarbon or a heterocyclic group.

2. A compound as claimed in claim 1 wherein R^2 represents an optionally substituted C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl or C_{3-7} heterocycloalkyl(C_{1-6})alkyl group; or aryl, aryl(C_{1-6})alkyl, aryl(C_{1-6})alkoxy, aryl(C_{2-6})alkenyl, aryl(C_{2-6})alkynyl, heteroaryl, heteroaryl(C_{1-6})alkyl, heteroaryl(C_{2-6})alkenyl or heteroaryl(C_{2-6})alkynyl, any of which groups may be optionally substituted on the aromatic moiety.
3. A compound as claimed in claim 1 represented by formula IIA, and salts and prodrugs thereof:

- 41 -



(IIA)

wherein

10

E and R are as defined in claim 1;

U represents $-(CH_2)_n-$, $-CH=CH-$ or $-C\equiv C-$;


n is zero, 1, 2 or 3;

 $-X-Y-$ represents $-CH_2-CH-$ or $-CH=C-$;


T represents a group of formula (i), (ii),

15

(iii), (iv), (v) or (vi):



(i)




(ii)




(iii)



(iv)



(v)



(vi)

in which V represents oxygen, sulphur or NH; and


35

 R^{13} and R^{17} independently represent hydrogen, halogen, cyano, nitro, trifluoromethyl, amino, C_{1-6}

- 42 -

alkylamino, di(C₁₋₆)alkylamino, C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl(C₁₋₆)alkoxy or C₂₋₆ alkylcarbonyl.

4. A compound as claimed in claim 1
 5 represented by formula IIB, and salts and prodrugs thereof:



(I I B)

wherein

E and R are as defined in claim 1;

A represents a moiety of formula $-(CH_2)_n-$,

20 $-CH=CH-$, $-C\equiv C-$, $-O-(CH_2)_m-$ or $-(CH_2)_m-O-$;


m is 1, 2 or 3; and

n, X, Y, R¹³ and R¹⁷ are as defined in claim 3.

5. A compound as claimed in claim 4 wherein R
 25 represents hydrogen and A represents $-C\equiv C-$, $-CH=CH-$ or
 $-O-(CH_2)_m-$.

6. A compound as claimed in claim 3 or claim
 4 represented by formula IIC, and salts and prodrugs
 30 thereof:

- 43 -



(IIC)


wherein

E is as defined in claim 1; and

n, X, Y, R¹³ and R¹⁷ are as defined in claim 3.

15

7. A compound as claimed in claim 1
represented by formula IID, and salts and prodrugs
thereof:



(IID)

wherein

30


E and Z are as defined in claim 1;

R¹³ is as defined in claim 3; and

R¹⁶ represents hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, aryl, aryl(C₁₋₆)alkyl or halogen.

- 44 -

8. A compound as claimed in claim 1 represented by formula IIE, and salts and prodrugs thereof:



(I I E)

wherein

15

E is as defined in claim 1;

R^{13} and R^{17} are as defined in claim 3; and

m is 1, 2 or 3.

9. A compound as claimed in claim 1 selected

20

from:

2-(1,2,3,4-tetrahydroisoquinolin-2-ylmethyl)-
benzimidazole;

2-[4-(2-phenylethyl)piperidin-1-ylmethyl]benzimidazole;

25

2-(4-phenyl-1,2,3,6-tetrahydropyrid-1-ylmethyl)-
benzimidazole;

5-chloro-2-(1,2,3,4-tetrahydroisoquinolin-2-
ylmethyl)benzimidazole;

5-methoxy-2-(1,2,3,4-tetrahydroisoquinolin-2-
ylmethyl)benzimidazole;

30

2-(1,2-dihydroisoindol-2-ylmethyl)benzimidazole;

2-(4-benzylpiperidin-1-ylmethyl)benzimidazole;

2-(4-benzyl-1,2,3,6-tetrahydropyrid-1-
ylmethyl)benzimidazole;

35

2-[4-(3-phenylpropyl)-1,2,3,6-tetrahydropyrid-1-
ylmethyl)benzimidazole;

- 45 -

- 2-[4-(2-phenylethyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
2-[4-(2-phenylethynyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
5 2-(4-benzyloxy-1,2,3,6-tetrahydropyrid-1-ylmethyl)benzimidazole;
2-[4-(3-phenylpropyl)piperidin-1-ylmethyl]benzimidazole;
2-(4-benzyloxypiperidin-1-ylmethyl)benzimidazole;
2-[4-(3-phenylpropylidene)piperidin-1-ylmethyl]benzimidazole;
10 2-[4-(E)-(2-phenylethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
1-methyl-2-[4-(E)-(2-phenylethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
15 2-[4-(benzothiophen-2-yl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
2-[4-(benzofuran-2-yl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
2-[4-(E)-(2-(thien-2-yl)ethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
20 2-[4-(E)-(2-(thien-3-yl)ethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
2-[4-(E)-(2-(furan-2-yl)ethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
25 2-[4-(E)-(2-(5-methylfuran-2-yl)ethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
2-[4-(E)-(2-(3-methoxyphenyl)ethenyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
2-(4-phenoxyethyl)-1,2,3,6-tetrahydropyrid-1-ylmethyl]benzimidazole;
30 and salts and prodrugs thereof.

10. A pharmaceutical composition comprising a compound as claimed in any one of the preceding claims in association with a pharmaceutically acceptable carrier.


- 46 -

11. A compound as claimed in any one of claims 1 to 9 for use in therapy.


12. The use of a compound as claimed in any one of claims 1 to 9 for the manufacture of a medicament for the treatment and/or prevention of disorders of the dopamine system.

13. A process for the preparation of a compound as claimed in claim 1, which comprises:

(A) reacting a compound of formula III with a compound of formula IV:



(III)




(IV)

wherein E, R, R³, R⁴ and R⁵ are as defined in claim 1, Q¹ represents the residue of a moiety of formula Qa to Qc as defined in claim 1, and L represents a suitable leaving group; or

(B) reducing a compound of formula V:


- 47 -



(V)

- 10 wherein R, R³, R⁴ and R⁵ are as defined in claim 1, Q¹ is as defined above, and E¹ represents a bond or a methylene group; or

- 15 (C) reacting a compound of formula III as defined above with a compound of formula VII:



(VII)

- 25 wherein R¹ and R² are as defined in claim 1; followed by treatment of the resulting pyridinium salt with a reducing agent; and

- 30 (D) subsequently, where required, converting a compound of formula I initially obtained into a further compound of formula I by conventional methods.

- 35 14. A method for the treatment and/or prevention of disorders of the dopamine system, which method comprises administering to a patient in need of

- 48 -

such treatment an effective amount of a compound as
claimed in any one of claims 1 to 9.

INTERNATIONAL SEARCH REPORT

Inter. Appl. Application No

PCT/GB 94/00528

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C07D235/14 C07D401/06 C07D409/14 C07D405/14 A61K31/415
A61K31/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 151 826 (JANSSEN PHARMACEUTICA N.V.) 21 August 1995 *See the general formula wherein L =Het, and examples 132 and 136, page54* ---	1,2,10, 11,13
X	DE,A,24 32 519 (BEECHAM GROUP LTD.) 30 January 1975 *see example 4 and page 6, 4th compound detailed therein* ---	1,2,10, 11,13
X	JP,A,1 052 718 (EISAI CO LTD.) 28 February 1989 cited in the application *see definition of X as CHOH and R as benzimidazole)* --- -/--	1,2,10, 11,13

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

A document member of the same patent family

Date of the actual completion of the international search

27 June 1994

Date of mailing of the international search report

08.07.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

PCT/GB 94/00528

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 449 187 (THE DU PONT MERCK PHARMACEUTICAL COMPANY) 2 October 1991 *see general formula I wherein Ar' may be benzimidazole* ---	1-13
A	EP,A,0 034 249 (GRUPPO LEPETIT S.P.A) 26 August 1981 *see example 17 and general formula* ---	1-13
A	EP,A,0 411 631 (MERRELL DOW PHARMACEUTICALS INC.) 6 February 1991 see the whole document -----	1-13

INTERNATIONAL SEARCH REPORT
 Information on patent family members

 Int. Appl. No.
 PCT/GB 94/00528

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0151826	21-08-85	AU-B- 573673	16-06-88
		AU-A- 3736485	12-09-85
		CA-A- 1259609	19-09-89
		DE-A- 3486121	06-05-93
		JP-A- 60185777	21-09-85
		SU-A- 1396964	15-05-88
		US-A- 4839374	13-06-89
		US-A- 4695575	22-09-87
DE-A-2432519	30-01-75	GB-A- 1417745	17-12-75
		AU-B- 475266	19-08-76
		AU-A- 7061174	08-01-76
		BE-A- 817328	06-01-75
		CH-A- 599198	12-05-78
		FR-A,B 2235690	31-01-75
		JP-A- 50069083	09-06-75
		NL-A- 7408584	09-01-75
		SE-B- 419861	31-08-81
		SE-A- 7407902	08-01-75
		US-A- 3960879	01-06-76
JP-A-1052718	28-02-89	NONE	
EP-A-0449187	02-10-91	US-A- 5169855	08-12-92
		JP-A- 4356462	10-12-92
EP-A-0034249	26-08-81	AU-B- 537378	21-06-84
		AT-T- 9999	15-11-84
		AU-A- 7188181	23-12-82
		CA-A- 1165762	17-04-84
		JP-C- 1682635	31-07-92
		JP-B- 3046467	16-07-91
		JP-A- 56125374	01-10-81
		US-A- 4360674	23-11-82
		US-A- 4461894	24-07-84
EP-A-0411631	06-02-91	AU-B- 625238	02-07-92
		AU-A- 6012390	07-02-91
		CA-A- 2022451	04-02-91
		DE-D- 69008069	19-05-94

Internal Application No
PCT/GB 94/00528

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0411631		JP-A- 3066683 US-A- 5064840	22-03-91 12-11-91

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.